Albert Kim

Endocrinologist @WestSydHealth
PhD Candidate @GarvanInstitute @UNSWMedicine

[Albert Kim @AlbertEndoc]

Uncovering the mechanisms driving the rebound phenomenon following denosumab discontinuation🦴
Excited to share our work showing an earlier 'window of opportunity' for sequential therapy
https://t.co/xeYFvji73d via @The_JBMR

@michbal19 @ArielCM14 @GarvanInstitute

[The Journal of Bone and Mineral Research @The_JBMR]

Thank you Dr. Kim @AlbertEndoc for your discussion of the mechanisms driving rebound #bone loss following denosumab discontinuation, from the April issue!
https://t.co/YRFZuRxIau
@ASBMR @OUPMedicine @michbal19 @ArielCM14
@GarvanInstitute

[Albert Kim @AlbertEndoc]

Thank you to the generous support by @EndoSocAus and Korean Endocrine Society to allow me to attend and present at #SICEM2024 on behalf of our wonderful team @michbal19 @ArielCM14

[Prof Natalie A Sims @NatalieASims]

Great job by @AlbertEndoc presenting his work, supervised by @michbal19 at #SICEM2024 @ANZBMS_ECIC #AusssieBoneHeads

[Albert Kim @AlbertEndoc]

Encouraged to see that the Korean Endocrine Society has a dedicated Committee of the Future Endocrinologist Sustainability (headed by Dr Jeonghoon Ha) who were keen to continue sharing ideas and strategies to potentially implement locally with @EndoSocAus

[Albert Kim @AlbertEndoc]

Thank you to #SICEM2024 for a dedicated session focussing on the challenges facing early career clinicians and researchers. Australian perspective presented by @NatalieASims with @EndoSocAus @ANZBMSoc input

[Albert Kim @AlbertEndoc]

Common barriers and challenges in promoting endocrinology to the next generation across Korea, Australia, Singapore and the US, including the need for better 'branding', improving remuneration:workload and better support throughout training.

[Albert Kim @AlbertEndoc]

Very excited to be attending and presenting at #SICEM2024

[Albert Kim @AlbertEndoc]

@DrJenLi_Renal Thanks Jen! 🙇

[Albert Kim @AlbertEndoc]

A massive THANK YOU to all our friends, colleagues, collaborators and funding bodies that support our work, and without whom this work would not have been possible! This study is opens up opportunities to explore our exciting hypotheses - stay tuned!

[Albert Kim @AlbertEndoc]

Denosumab is a great medication to treat osteoporosis and prevent fractures but stopping treatment leads to a rebound loss in bone and increased risk of fractures. Current strategies to prevent this have not worked and we used our mouse model to show why:

[Albert Kim @AlbertEndoc]

Overall, we show that the drivers of the rebound phenomenon are in play before BMD loss is detectable. Waiting for BMD loss or CTX rise is likely too late to intervene to stop this process! A rise in TRAP occurs earlier and this may be a better marker in this context!

[Albert Kim @AlbertEndoc]

Uncovering the mechanisms driving the rebound phenomenon following denosumab discontinuation🦴
Excited to share our work showing an earlier 'window of opportunity' for sequential therapy
https://t.co/xeYFvji73d via @The_JBMR

@michbal19 @ArielCM14 @GarvanInstitute

[Lisa Mary Raven @lisamaryraven]

Our case of #SGLT2 inhibitor associated ketoacidosis in a patient without diabetes. These medications have so many benefits 🫀🫘🏥 but pharmacovigilance is also important @SVHSydney @GarvanInstitute @VictorChangInst

[Endocrine Society of Australia @EndoSocAus]

Less than a week to go until #ESASRB23 - we can’t wait to see you there! Last chance to register!

[Dr Ayse Zengin @DrAyseZ]

Pro-osteoclastogenic environment is in place before rebound bone loss is clinically detectable by serum bone turnover markers - nice talk by @michbal19

#ANZBMS2023
@ANZBMS_ECIC
@ANZBMSoc